Amy Jamieson, Marcel Grube, Samuel Leung, Derek Chiu, Amy Lum, Janice S Kwon, Aline Talhouk, Blake Gilks, Stefan Kommoss, Jessica N McAlpine
OBJECTIVES: Optimal management of patients with stage IA p53abn endometrial cancer without myoinvasion, classified as intermediate risk in the 2020 European Society of Gynaecological Oncology, European Society for Radiotherapy and Oncology, and European Society of Pathology (ESGO-ESTRO-ESP) guidelines, and the 2022 European Society of Medical Oncology (ESMO) guidelines, is currently unclear. Practice varies from surgery alone to adjuvant radiation±chemotherapy. Our aim was to assess the risk of disease recurrence in patients with stage IA p53abn endometrial cancer without myoinvasion compared with stage IA with myoinvasion (<50%)...
February 22, 2024: International Journal of Gynecological Cancer